Literature DB >> 17667613

Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye.

Calvin W Roberts1, Patricia E Carniglia, Brian G Brazzo.   

Abstract

PURPOSE: To compare the efficacy of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye.
METHODS: Patients with dry eye (N = 30) seen in a university-affiliated private practice were randomized to 1 of 3 treatments: cyclosporine 0.05% ophthalmic emulsion (RESTASIS) twice daily, lower-lid punctal plugs (PARASOL), or a plugs-cyclosporine combination. Tear volume, ocular surface staining, and artificial tear use were assessed at baseline and 1, 3, and 6 months.
RESULTS: All treatments improved Schirmer scores by 6 months (P < or = 0.005 vs. baseline), with plug-containing regimens favored at 1 and 3 months (P < 0.001 vs. cyclosporine alone). Cyclosporine-containing regimens, but not plugs alone, improved rose bengal staining at 3 and 6 months (P < or = 0.010 vs. baseline). Artificial tear use decreased with plug-containing regimens at 1 month and with all treatments at 3 and 6 months (P < or = 0.005 vs. baseline). Combination therapy produced the greatest overall improvements and was superior to plugs alone in decreasing artificial tear use at 6 months (P = 0.012).
CONCLUSIONS: All 3 regimens effectively treated dry eye. Plug-containing regimens increased wetness initially; cyclosporine appeared to promote long-term ocular surface health. The effects may be additive. Patients with punctal occlusion may benefit from adjunctive cyclosporine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17667613     DOI: 10.1097/ICO.0b013e318074e460

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  23 in total

Review 1.  Topical and systemic medications for the treatment of primary Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Antoni Sisó-Almirall; Xavier Bosch; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

2.  Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease.

Authors:  Consuelo Pérez-Rico; Francisco Germain; María Castro-Rebollo; Agustín Moreno-Salgueiro; Miguel Ángel Teus
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

3.  Punctal occlusion in Sjögren's syndrome needs clarification.

Authors:  Eduardo M Rocha; Jayter S Paula; Peter S Reinach
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

4.  Neurostimulation of the lacrimal nerve for enhanced tear production.

Authors:  Andrea L Kossler; Jianhua Wang; William Feuer; David T Tse
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Mar-Apr       Impact factor: 1.746

Review 5.  Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.

Authors:  Olivia L Lanier; Miranda G Manfre; Claire Bailey; Zhen Liu; Zachary Sparks; Sandesh Kulkarni; Anuj Chauhan
Journal:  AAPS PharmSciTech       Date:  2021-03-14       Impact factor: 3.246

Review 6.  The pathophysiology, diagnosis, and treatment of dry eye disease.

Authors:  Elisabeth M Messmer
Journal:  Dtsch Arztebl Int       Date:  2015-01-30       Impact factor: 5.594

Review 7.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

8.  Dry eye disease: A review of diagnostic approaches and treatments.

Authors:  Hui Lin; Samuel C Yiu
Journal:  Saudi J Ophthalmol       Date:  2014-06-24

9.  Cataract surgery in patients with ocular surface disease: An update in clinical diagnosis and treatment.

Authors:  Neda Afsharkhamseh; Asadolah Movahedan; Hooman Motahari; Ali R Djalilian
Journal:  Saudi J Ophthalmol       Date:  2014-07-04

10.  The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca.

Authors:  Koray Gumus; Dwight H Cavanagh
Journal:  Clin Ophthalmol       Date:  2009-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.